Agile Therapeutics (AGRX)

Company website 2020 Financial Report Stock Analysis

3500

Prescribers

of Agile's approved contraceptive Twirla as of November 2021

1.3

Million Dollars

in net product sales in 2021 Q3

21.1

Million Dollars

Agile recently raised an additional $21.2 million in a public offering

View Our Analysis

The Path to Drawdown: Contraceptives

Approximately 225 million women in lower-income countries lack the ability to choose whether and when to become pregnant. That leads to some 75 million unintended pregnancies each year. There's a similar deficiency in contraceptives in high-income countries, too. In the United States, for example, nearly half of all pregnancies are unintended.

Securing the right to voluntary, high-quality family planning services and contraception around the world would have significant beneficial impacts on the health, welfare, and life expectancy of both women and their children.

Contraceptives, family planning and resources for women's health would also hugely benefit the environment. Every person in the world consumes resources and causes emissions throughout their life. If contraceptives are widely provided and women's health are secured, a more stable population size could help avoid up to 85.42 gigatons of greenhouse gases between 2020 and 2050.

About

Agile Therapeutics (stock ticker: AGRX) is a women's healthcare company that offers a prescription combination hormonal contraceptive patch. Agile is headquartered in Princeton, New Jersey.

AGRX's Role in Drawdown

Agile's flagship product, Twirla, is a once-weekly prescription combination hormonal contraceptive patch that delivers a dose of estrogen consistent with commonly prescribed combined hormonal contraceptives, and lower than the estrogen dose found in other patches on the market. Twirla was approved by the FDA in February 2020 as a method of contraception for use in women of reproductive potential.

Women's health is a Drawdown solution - by giving women the right over family planning, this solution helps humanity conserve resources and slow emissions in the long-run.

AGRX: What We Like

Agile's website has an ESG page, but it doesn't include substantive climate-related information and data. We'll update this section once they provide more sustainability information.

What We Want to See Improve

Disclose Sustainability Metrics

While Agile Therapeutics doesn't own any manufacturing facilities (p. 14), we still want to know the carbon footprint of their R&D and manufacturing process. We'd like to see Agile Therapeutics publish an annual sustainability report that includes their absolute greenhouse gas emissions and sources of energy use. Their ESG page mentions that Agile Therapeutics supported several green measures in an effort to reduce their carbon footprint in their corporate office. We'd like to know more about these measures, too.

Set Clear Targets

Once sustainability metrics are disclosed, we'd like to see Agile Therapeutics set forth commitments for reducing their carbon footprint. These targets should be in line with the world's commitment to stay below 1.5°C of global warming by mid-century, and accompanied by the specific steps Agile Therapeutics will take to achieve these goals and the timeframe by which they'll be achieved.

Related Birth Control Stocks in the Climate Index

View All Climate Index Stocks →

Allocated	Company	Description
0.03%	Veru, Inc. (VERU)	Very makes female condoms used by the United Nations that protect against unintended pregnancies and STIs. Women’s health is a valuable Drawdown solution
0.02%	Agile Therapeutics (AGRX)	Agile offers a contraceptive patch that gives women the right to family planning. Family planning is a key Drawdown solution for sustainability
0.02%	Evofem Biosciences, Inc. (EVFM)	Evofem makes a hormone-free contraceptive vaginal gel that gives women control over their reproductive health. Women’s health is a key Drawdown solution